Total trials
471
Active
183
Phase 3
40
Total enrollment
383,739
Pipeline matrix
Showing 40 of 51 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methotrexate | — | — | — | — | 5 | ||
| Prednisone | — | — | — | — | — | 1 | |
| Cyclosporin | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 | |
| H1 Antihistaminics | — | — | — | — | — | 1 | |
| Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks | — | — | — | — | — | 1 | |
| Olimel N12 | — | — | — | — | — | 1 | |
| Glucose IV | — | — | — | — | — | 1 | |
| Atorvastatin | — | — | — | — | — | 1 | |
| Double dosing of beta-lactam antibiotic | — | — | — | — | — | 1 | |
| Intravenous ferric carboxymaltose | — | — | — | — | — | 1 | |
| Gardasil 9 Suspension for | — | — | — | — | — | 1 | |
| Fentanyl | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | 4 | ||
| Atropine Ophthalmic 0.05% | — | — | — | — | — | 1 | |
| Atropine Ophthalmic 0.5% | — | — | — | — | — | 1 | |
| Leucovorin Calcium | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| Irinotecan Hydrochloride | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Adjuvant chemotherapy | — | — | — | — | — | 1 | |
| Doxapram | — | — | — | — | — | 1 | |
| Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | 3 | |||
| Pyrimethamine | — | — | — | — | — | 2 | |
| Topiramate | — | — | — | — | — | 2 | |
| Avelumab | — | — | — | — | — | 1 | |
| ISA104 | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Esmolol | — | — | — | — | — | 1 | |
| Adoptive therapy with autologous MC2 TCR T cells | — | — | — | — | — | 1 | |
| Secretin administration during ex-situ liver machine perfusion | — | — | — | — | — | 1 | |
| Talazoparib | — | — | — | — | — | 1 | |
| FLOT-CROSS or CROSS-FLOT | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Docetaxel or cabazitaxel | — | — | — | — | — | 1 | |
| cRGD-ZW800-1. | — | — | — | — | — | 1 | |
| intraperitoneal chemotherapy | — | — | — | — | — | 1 | |
| Hepatic Arterial Infusion Pump chemotherapy with floxuridin | — | — | — | — | — | 1 | |
| CRGD-ZW800-1 | — | — | — | — | — | 1 |
11 more active programs hidden
Next readouts
- 2023-11-01
- 2024-04-02
- 2024-08-13
- 2024-12-20
- 2025-04
- 2025-05-01
- 2025-08
- 2025-11-01
- 2025-12
- 2025-12-01
Top conditions
- Coronary Artery Disease11
- Anxiety9
- Quality of Life8
- Aortic Valve Stenosis7
- Glioblastoma6
- Heart Failure6
- Depression6
- Hypertension6
Frequently asked questions about Erasmus Medical Center
- How many clinical trials does Erasmus Medical Center have on ClinicalTrials.gov?
- Erasmus Medical Center is listed as the lead sponsor on 471 clinical trials in ClinicalTrials.gov, 183 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Erasmus Medical Center's trials are in Phase 3?
- 40 of Erasmus Medical Center's trials are in Phase 3, spread across 51 active drug programs.
- What therapeutic areas does Erasmus Medical Center focus on?
- Erasmus Medical Center's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Anxiety, Quality of Life, Aortic Valve Stenosis, Glioblastoma.
- When are Erasmus Medical Center's next clinical trial readouts?
- Erasmus Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study”, expected around 2023-11-01.